Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD EPS (Basic)

EPS (Basic) at other companies

Biogen logo
BiogenBIIB
$2.17+31.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.97+2,363%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0.52+10.6%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$0.03-100%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%
TG Therapeutics logo
TG TherapeuticsTGTX
$0.14+367%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's EPS (basic)?
Acadia Pharmaceuticals (ACAD) reported EPS (basic) of $0.02 in Q1 2026.
How has Acadia Pharmaceuticals's EPS (basic) changed year-over-year?
Acadia Pharmaceuticals's EPS (basic) decreased by 81.8% year-over-year, from $0.11 to $0.02.
What is the long-term trend for Acadia Pharmaceuticals's EPS (basic)?
Over 4 years (2021 to 2025), Acadia Pharmaceuticals's EPS (basic) has grown at a 21.9% compound annual growth rate (CAGR), from -$1.05 to $2.32.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.